Company Encyclopedia
View More
name
TASLY
600535.SH
Tasly Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells medicines and related pharmaceuticals in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is based in Tianjin, China.
3.157 T
600535.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking13/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.78%B
    • Profit Margin13.15%B
    • Gross Margin66.18%A
  • Growth ScoreD
    • Revenue YoY-2.56%D
    • Net Profit YoY24.60%B
    • Total Assets YoY-11.15%E
    • Net Assets YoY-3.97%D
  • Cash ScoreC
    • Cash Flow Margin760.30%B
    • OCF YoY-2.56%D
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreA
    • Gearing Ratio16.43%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tasly Pharmaceutical's Q3 Profit Rises 17%, Revenue Slips 3%; Shares Down 1%

    Tasly Pharmaceutical's Q3 Profit Rises 17%, Revenue Slips 3%; Shares Down 1%

    marketscreener·
    SH
    600535
    +0.20%
    marketscreener·
    SH
    600535
    +0.20%

    Tasly Pharmaceutical’s Nine-Month Financials Show Increased Profit

    Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials indicate positive cash flow and a stable asset base, reflecting a solid financial position. This could influence China Resources Pharmaceutical Group’s market standing and investor confidence, as the group holds a 28% equity interest in Tasly. Current market cap for China Resources is HK$30.6B with a technical sentiment signal to sell.

    Tip Ranks·
    SH
    600535
    +0.20%
    Tip Ranks·
    SH
    600535
    +0.20%

    Tasly pharmaceutical group Q3 net profit up 16.6% Y/Y

    Tasly pharmaceutical group Q3 net profit up 16.6% Y/Y

    marketscreener·
    SH
    600535
    +0.20%
    marketscreener·
    SH
    600535
    +0.20%

    TASLY: The net profit for the third quarter was 210 million yuan, a year-on-year increase of 16.56%

    TASLY announced that its revenue for the third quarter was 2.022 billion yuan, a year-on-year decrease of 3.27%; net profit was 210 million yuan, a year-on-year increase of 16.56%. Revenue for the first three quarters was 6.311 billion yuan, a year-on-year decrease of 2.35%; net profit was 984 million yuan, a year-on-year increase of 16.88%

    Zhitong·
    SH
    600535
    +0.20%
    Zhitong·
    SH
    600535
    +0.20%

    Tasly Pharmaceutical Gets Drug Registration Certificate for Wenjing Decoction Granules

    Tasly Pharmaceutical Gets Drug Registration Certificate for Wenjing Decoction Granules

    marketscreener·
    SH
    600535
    +0.20%
    marketscreener·
    SH
    600535
    +0.20%
    © 2025 Longbridge｜Disclaimer